Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Proprietary Name Review Acceptance Memorandum - Anascorp


Our STN: 125335/0 
Instituto Bioclon, S.A. de C.V.
Attention: -----(b)(4)------------
Dear -----(b)(4)----:
We have reviewed your submission dated February 12, 2009 to your biologics license application (BLA) for Centruroides (Scorpion) Immune F(ab)2 Intravenous (Equine) requesting a proprietary name review.
In consultation with CBER’s Advertising and Promotional Labeling Branch (APLB), we have considered your proposed proprietary name Anascorp and conclude that under 21 CFR Part 201 the proposed proprietary name is acceptable with concerns at this time. There is a potential risk for medication error with Aranesp; however, these risks may be minimized by providing packaging that will differentiate Anascorp from Aranesp.
If you have any questions, please contact Debbie Cordaro at (301) 827-6157.
Sincerely yours,

Basil Golding, M.D.
Division of Hematology
Office of Blood Research and Review
Center for Biologics
Evaluation and Research


Page Last Updated: 03/25/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English